Get the Stockscreener App
3.1145
0.32%
0.0145
Vistagen Therapeutics Inc stock is traded at $3.1145, with a volume of 178.18K.
It is up +0.32% in the last 24 hours and up +21.96% over the past month.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
See More
Previous Close:
$3.10
Open:
$3.06
24h Volume:
178.18K
Relative Volume:
0.46
Market Cap:
$95.56M
Revenue:
$875.70K
Net Income/Loss:
$-39.57M
P/E Ratio:
-2.3203
EPS:
-1.3423
Net Cash Flow:
$-33.65M
1W Performance:
+5.25%
1M Performance:
+21.96%
6M Performance:
+6.14%
1Y Performance:
-13.61%
1-Day Range:
$3.00
$3.175
1-Week Range:
$2.95
$3.58
52-Week Range:
$1.90
$3.79
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Name
Vistagen Therapeutics Inc
Sector
Industry
Phone
650-577-3600
Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
3.1148 | 104.31M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
398.68 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.25 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.54 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
662.12 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
314.00 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-07-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Upgrade | Maxim Group | Hold → Buy |
| Jul-22-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-22-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-20-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Initiated | Jefferies | Buy |
| Jan-04-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Feb-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-28-17 | Initiated | Maxim Group | Buy |
View All
Vistagen Therapeutics Inc Stock (VTGN) Latest News
VistaGen Therapeutics (NASDAQ:VTGN) Rating Increased to Hold at Wall Street Zen - MarketBeat
Can Vistagen Therapeutics Inc. Bounce Back From Weekly Low2025 Geopolitical Influence & Long Hold Capital Preservation Tips - Newser
Is now a turning point for Vistagen Therapeutics Inc.Weekly Earnings Recap & AI Enhanced Trading Signals - Newser
Analyzing recovery setups for Vistagen Therapeutics Inc. investorsEarnings Trend Report & Weekly High Return Forecasts - Newser
What to do if you’re stuck in Vistagen Therapeutics Inc.Portfolio Value Report & Stock Portfolio Risk Control - Newser
Vistagen Therapeutics Inc.’s volatility index tracking explained2025 Trade Ideas & Accurate Buy Signal Notifications - Newser
Earnings visualization tools for Vistagen Therapeutics Inc.Market Volume Report & Accurate Intraday Trade Tips - Newser
Volatility clustering patterns for Vistagen Therapeutics Inc.2025 Winners & Losers & Weekly Setup with High ROI Potential - Newser
How to build a custom watchlist for Vistagen Therapeutics Inc.Weekly Gains Summary & Verified Entry Point Signals - Newser
Using AI based signals to follow Vistagen Therapeutics Inc.Market Sentiment Report & Weekly Top Performers Watchlists - Newser
Can trapped investors hope for a rebound in Vistagen Therapeutics Inc.Bull Run & Technical Entry and Exit Alerts - Newser
How to interpret RSI for Vistagen Therapeutics Inc. stockShare Buyback & Stock Portfolio Risk Management - Newser
Using Python tools to backtest Vistagen Therapeutics Inc. strategiesWeekly Profit Summary & Verified Entry Point Signals - Newser
What candlestick patterns are forming on Vistagen Therapeutics Inc.GDP Growth & Safe Entry Trade Reports - Newser
Heatmap analysis for Vistagen Therapeutics Inc. and competitorsTrade Exit Report & Comprehensive Market Scan Insights - Newser
Vistagen Therapeutics Inc. stock outlook for YEAREarnings Growth Report & Community Verified Swing Trade Signals - Newser
Intraday pattern recognizer results for Vistagen Therapeutics Inc.Weekly Loss Report & High Return Stock Watch Alerts - Newser
Will Vistagen Therapeutics Inc. see short term momentum2025 Analyst Calls & Trade Opportunity Analysis Reports - Newser
Why Vistagen Therapeutics Inc. stock attracts strong analyst attentionExit Point & Expert Approved Momentum Ideas - Newser
How to track smart money flows in Vistagen Therapeutics Inc.Portfolio Value Summary & AI Based Buy/Sell Signal Reports - Newser
Is Vistagen Therapeutics Inc. trending in predictive chart modelsWeekly Profit Recap & Weekly Breakout Watchlists - Newser
Retail Investors Hold Significant Control Over Vistagen Therapeutics, Inc. - AInvest
retail investors who own 49% along with institutions invested in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) saw increase in their holdings value last week - simplywall.st
Technical analysis overview for Vistagen Therapeutics Inc. stockJuly 2025 Summary & Free Safe Entry Trade Signal Reports - Newser
Using R and stats models for Vistagen Therapeutics Inc. forecastingAnalyst Upgrade & Free Expert Verified Stock Movement Alerts - Newser
Evaluating Vistagen Therapeutics Inc. with trendline analysisWeekly Trade Review & Fast Moving Stock Trade Plans - Newser
Is Vistagen Therapeutics Inc. stock a good hedge against inflationJuly 2025 Highlights & Real-Time Market Sentiment Alerts - Newser
Vistagen Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
What makes Vistagen Therapeutics Inc. stock attractive to long term investorsRate Cut & Verified Momentum Watchlists - Newser
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2026 Earnings Call Transcript - MSN
Vistagen Therapeutics Inc. Q1 Earnings Call Highlights: Progress Amid Challenges and Financial Pressures. - AInvest
VistaGen Therapeutics (NASDAQ:VTGN) Posts Quarterly Earnings Results - MarketBeat
Vistagen (VTGN) Q1 R&D Expense Jumps 54% - AOL.com
Published on: 2025-08-12 05:18:03 - Newser
Is Vistagen Therapeutics Inc. stock a good dividend stockGame-Changing Investment Alerts - thegnnews.com
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates - MSN
Vistagen Therapeutics Inc Stock (VTGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.33%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):